한국지질동맥경화학회 학술대회

Insulin resistance is a key pathophysiology underlying metabolic disorders and is closely associated with the development of atherosclerotic cardiovascular disease (ASCVD). The triglyceride-glucose (TyG) index is a novel and simple surrogate marker of insulin resistance, calculated using fasting triglyceride and glucose levels, and has demonstrated comparable accuracy to HOMA-IR. In this session, we will explore the clinical role of the TyG index based on recent national and international studies regarding its predictive value for ASCVD. Professor Patricio Lopez-Jaramillo from Universidad de Santander, Colombia, will present multinational data on the association between the TyG index and ASCVD. Professor Yong-Jae Lee from Yonsei University College of Medicine, Republic of Korea, will share findings from Korean data on the same topic. Finally, Professor Ki-Bum Won from Chung-Ang University College of Medicine, Republic of Korea, will offer a lecture on the relationship between the TyG index and coronary artery calcification.

Professor Ioanna Gouni-Berthold is a distinguished Professor of Internal Medicine and Endocrinology at the University of Cologne, Germany, and a leading member of the Center for Endocrinology, Diabetes and Preventive Medicine at the University Hospital of Cologne. Her clinical and research expertise lies in lipid metabolism, dyslipidemia, cardiovascular risk management, and metabolic diseases. Professor Gouni-Berthold has contributed extensively to the field through numerous publications in high-impact journals and active involvement in international clinical trials and guideline development committees. At ICoLA 2025, she has been invited as a Plenary Lecturer to present on the topic: “Advances in lipid-lowering therapy: shaping the future of cardiovascular prevention.” In this lecture, Professor Gouni-Berthold will discuss the most recent advances in lipid-lowering therapies, highlighting their mechanisms of action, clinical trial data, and potential to reshape current paradigms in cardiovascular prevention.

Professor Ki-Hyun Jeon from Seoul National University, Republic of Korea, is a leading expert in digital health and medical informatics, with a particular focus on applying artificial intelligence to clinical data and research processes. He has recently garnered wide attention for pioneering the integration of generative AI tools such as ChatGPT into real-world medical research, manuscript drafting, and data interpretation workflows. In ICoLA 2025, Professor Jeon will deliver a Special Lecture titled “Integrating ChatGPT into medical and clinical research workflows.” This session will highlight practical use cases, emerging methodologies, and the potential impact of AI-powered tools on the future of evidence generation and scientific communication in medicine. His insights will be especially valuable for clinicians and researchers seeking to incorporate cutting-edge technology into their research environments.

In this lecture, Dr. Ljubica Matic will present on “Multi-omics data integration from patients with carotid stenosis illuminates key molecular signatures of atherosclerotic instability,” introducing the current applications of various omics technologies in understanding the complex biological mechanisms underlying vascular diseases. Through integrated analysis of genomic, transcriptomic, proteomic, metabolomic, and epigenomic data, she will demonstrate comprehensive methodological approaches for in-depth characterization of molecular pathways involved in major vascular conditions including atherosclerosis, hypertension, and vascular remodeling. Drawing from recent advances in transcriptomics and systems biology research, Dr. Matic will explain how multi-omics approaches serve as critical bridges in translational research between basic science discoveries and clinical applications. This presentation will share cutting-edge research findings on the identification of novel biomarkers, regulatory network analysis, and therapeutic target discovery related to vascular diseases, and will provide a platform for interdisciplinary collaboration and in-depth academic discourse in the field of vascular medicine.

This session entitled “Emerging Drugs for Dyslipidemia Management” addresses innovative pharmacological strategies to tackle residual lipid risk that persists despite statin therapy. While LDL-C reduction remains the cornerstone of dyslipidemia management, a substantial number of patients continue to face elevated cardiovascular risk due to hypertriglyceridemia, elevated remnant cholesterol, or persistent atherogenic dyslipidemia. The first lecture will examine the real-world clinical applications of bempedoic acid and identify patient populations who may derive maximum therapeutic benefit. The second lecture will focus on APOC3 inhibition strategies for severe hypertriglyceridemia management, discussing clinical applicability in familial chylomicronemia syndrome and mixed dyslipidemia with supporting evidence from recent clinical trials. The final lecture will present the regulatory mechanisms of ANGPTL3 and ANGPTL8 in lipid metabolism and introduce the development status of next-generation therapeutic approaches targeting these pathways. Through this session, attendees will gain comprehensive insights into the latest paradigms in lipid-lowering therapy and future prospects for clinical implementation.

Professor Kausik Kumar Ray is a Professor of Public Health and Primary Care at Imperial College London and Honorary Consultant Cardiologist at Imperial College NHS Trust. He is the Immediate Past President of the European Atherosclerosis Society and the Chair of the World Heart Federation Cholesterol Roadmap Committee. As a globally recognized expert in clinical trials and epidemiological research, his work has been cited over 178,000 times worldwide. In this plenary lecture titled “Cholesterol lowering throughout the life-course to prevent atherosclerotic cardiovascular disease-a pragmatic population health approach,” Professor Ray will highlight the importance of lipid management across the entire life course. The session will explore evidence-based strategies for the prevention of atherosclerotic cardiovascular disease (ASCVD), emphasizing a pragmatic and population-wide approach to cholesterol reduction.

In Keynote Lecture 2, Professor Jacob Fog Bentzon from Aarhus University, Denmark, will present his latest findings on “The role of smooth muscle cells in atherosclerotic plaque progression.” As a global authority in experimental atherosclerosis research, Professor Bentzon leads a team focused on uncovering the cellular mechanisms of atherosclerosis and identifying novel therapeutic targets. This lecture will explore the heterogeneity and phenotypic modulation of smooth muscle cells within atherosclerotic plaques and their impact on plaque stability and cardiovascular events. Bridging fundamental science and clinical relevance, this keynote will provide critical insights for those seeking to understand the pathobiology of atherosclerosis and to develop future treatment strategies.

Professor Hong June Yoo, Endowed Director General, National Museum of Korea, Republic of Korea, is a leading scholar who has played a pivotal role in bringing Korean art history and garden culture to the public. In this special lecture, Professor Yoo will explore the aesthetic differences between Eastern and Western approaches to gardens, and introduce the uniquely nature-oriented philosophy embodied in traditional Korean gardens. This lecture offers a unique opportunity to reflect on how Korean gardens express a deep respect for nature and reveal a way of life that seeks harmony with the natural world.

“Dyslipidemia Management in Special Populations” explores lipid-lowering strategies tailored to unique clinical contexts. Professor Mina Kim (Korea University, Republic of Korea) will address dyslipidemia management in women before and after menopause, highlighting hormonal influences on cardiovascular risk. Professor Byung Sik Kim (Hanyang University, Republic of Korea) will discuss lipid management in patients with liver disease, focusing on the safe and effective use of statins in this vulnerable group. Finally, Professor Seonghoon Choi (Hallym University, Republic of Korea) will present on dyslipidemia in the setting of HIV infection and chronic inflammation, emphasizing pathophysiological mechanisms and therapeutic challenges. This session will provide practical insights into individualized dyslipidemia care for patients with complex comorbidities and diverse physiological backgrounds.